Teva Pharmaceuticals has received FDA approval to market generic asthma treatment, Globes reported on Sunday.
Teva Pharmaceutical Industries Ltd.is one of ten companies to obtain US Food and Drug Administration (FDA) approval for a version of Merck's asthma and allergies drug Singulair in adults and children. Brand Singulair, made by Merck & Co., has $5 billion in annual US sales.
Teva obtained approval for both tablet and oral granule forms of Singulair. Sandoz will reportedly launch cheaper generic versions of the drug, which will jointly win 66% of the market.
Montelukast, the active ingredient in the drug, is in a class of medications called leukotriene receptor antagonists. It works by blocking the action of leukotrienes, substances in the body that cause the symptoms of asthma and hay fever (allergic rhinitis).